[The quality of life dynamics in patients with gastroesophageal reflux disease during rabeprazol therapy].
The present article represents findings of quality of life index dynamics for 100 patients with gastroesophageal reflux disease under pressure of proton pump inhibitor therapy. The degree of clinical evidence was measured by Likert scale, quality of life appraisal was made on the bases of SF-36, GSRS checklists, psychoemotional component of patients' health was analyzed with the help of the V.M. Bekhterev Institute personal enquirer. Treatment with Rabeprazole helps efficiently jugulate reflux disease symptoms and accurately improve quality of life index.
Maev
I V
IV
Samsonov
A A
AA
Odintsova
A N
AN
Golubev
N N
NN
Iablunovskaia
G I
GI
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life / Q000523:psychology*; D064750:Rabeprazole; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D055815:Young Adult
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064750:Rabeprazole